Department of Cardiovascular Medicine, Hangzhou Lin'an District People's Hospital, 548 Yijin Road, Lin'an, Hangzhou, Zhejiang, 311300, China.
Department of Endocrinology, Shanxian Dongda Hospital, 001 Shunshi East Road, Shanxian, Shandong, China.
Mol Cell Probes. 2020 Aug;52:101558. doi: 10.1016/j.mcp.2020.101558. Epub 2020 Mar 5.
Diabetic cardiomyopathy (DCM) is a common complication of diabetes mellitus that can cause many severe symptoms, such as heart failure, arrhythmia, and sudden death. However, the molecular mechanisms underlying cardiac dysfunction in DCM remain elusive. In this study, we found that miR-410-5p was increased in the myocardial tissue of a diabetes mellitus (DM) rat model. Further studies confirmed that inhibition of miR-410-5p reduced cell apoptosis by regulating the Bcl-2/Bax axis. Through bioinformatics analysis and luciferase reporter assays, we observed that miR-410-5p directly targets PIM1. Moreover, knockdown of miR-410-5p by antagomir-410-5p improved diabetes-induced cardiac function and myocardial tissue structure. In conclusion, our study demonstrated that miR-410-5p might be involved in the progression of DCM by targeting PIM1 and might be a promising therapeutic target for DCM in the future.
糖尿病心肌病(DCM)是糖尿病的一种常见并发症,可导致许多严重的症状,如心力衰竭、心律失常和猝死。然而,DCM 中心脏功能障碍的分子机制仍不清楚。在这项研究中,我们发现 miR-410-5p 在糖尿病(DM)大鼠模型的心肌组织中增加。进一步的研究证实,抑制 miR-410-5p 通过调节 Bcl-2/Bax 轴减少细胞凋亡。通过生物信息学分析和荧光素酶报告基因实验,我们观察到 miR-410-5p 可直接靶向 PIM1。此外,通过 antagomir-410-5p 抑制 miR-410-5p 可改善糖尿病引起的心脏功能和心肌组织结构损伤。总之,我们的研究表明,miR-410-5p 可能通过靶向 PIM1 参与 DCM 的进展,并且可能成为未来 DCM 的有前途的治疗靶点。